Searched for: in-biosketch:true
person:hoffmr05
Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement
Roberts, Darren M; Yates, Christopher; Megarbane, Bruno; Winchester, James F; Maclaren, Robert; Gosselin, Sophie; Nolin, Thomas D; Lavergne, Valery; Hoffman, Robert S; Ghannoum, Marc
OBJECTIVE: Methanol poisoning can induce death and disability. Treatment includes the administration of antidotes (ethanol or fomepizole and folic/folinic acid) and consideration of extracorporeal treatment for correction of acidemia and/or enhanced elimination. The Extracorporeal Treatments in Poisoning workgroup aimed to develop evidence-based consensus recommendations for extracorporeal treatment in methanol poisoning. DESIGN AND METHODS: Utilizing predetermined methods, we conducted a systematic review of the literature. Two hundred seventy-two relevant publications were identified but publication and selection biases were noted. Data on clinical outcomes and dialyzability were collated and a two-round modified Delphi process was used to reach a consensus. RESULTS: Recommended indications for extracorporeal treatment: Severe methanol poisoning including any of the following being attributed to methanol: coma, seizures, new vision deficits, metabolic acidosis with blood pH =7.15, persistent metabolic acidosis despite adequate supportive measures and antidotes, serum anion gap higher than 24 mmol/L; or, serum methanol concentration 1) greater than 700 mg/L (21.8 mmol/L) in the context of fomepizole therapy, 2) greater than 600 mg/L or 18.7 mmol/L in the context of ethanol treatment, 3) greater than 500 mg/L or 15.6 mmol/L in the absence of an alcohol dehydrogenase blocker; in the absence of a methanol concentration, the osmolal/osmolar gap may be informative; or, in the context of impaired kidney function. Intermittent hemodialysis is the modality of choice and continuous modalities are acceptable alternatives. Extracorporeal treatment can be terminated when the methanol concentration is <200 mg/L or 6.2 mmol/L and a clinical improvement is observed. Extracorporeal Treatments in Poisoning inhibitors and folic/folinic acid should be continued during extracorporeal treatment. General considerations: Antidotes and extracorporeal treatment should be initiated urgently in the context of severe poisoning. The duration of extracorporeal treatment extracorporeal treatment depends on the type of extracorporeal treatment used and the methanol exposure. Indications for extracorporeal treatment are based on risk factors for poor outcomes. The relative importance of individual indications for the triaging of patients for extracorporeal treatment, in the context of an epidemic when need exceeds resources, is unknown. In the absence of severe poisoning but if the methanol concentration is elevated and there is adequate alcohol dehydrogenase blockade, extracorporeal treatment is not immediately required. Systemic anticoagulation should be avoided during extracorporeal treatment because it may increase the development or severity of intracerebral hemorrhage. CONCLUSION: Extracorporeal treatment has a valuable role in the treatment of patients with methanol poisoning. A range of clinical indications for extracorporeal treatment is provided and duration of therapy can be guided through the careful monitoring of biomarkers of exposure and toxicity. In the absence of severe poisoning, the decision to use extracorporeal treatment is determined by balancing the cost and complications of extracorporeal treatment to that of fomepizole or ethanol. Given regional differences in cost and availability of fomepizole and extracorporeal treatment, these decisions must be made at a local level.
PMID: 25493973
ISSN: 0090-3493
CID: 1440952
Evaluating Patients' Understanding of Printed Warfarin Medication Information
Schwartz, Lauren; Mazzola, Nissa; Hoffman, Robert S; Howland, Mary Ann; Mercurio-Zappala, Maria; Nelson, Lewis S
OBJECTIVE: Warfarin is a high-risk medication whose safe use may be greatly improved by patient education. This study evaluate evaluated patients' understanding of warfarin instructions, medication management, the Food and Drug Administration's (FDA) warfarin medication guide content, and patient information recommendations. METHODS: Interviews conducted at 2 hospital-based outpatient primary care sites with patients initiated on warfarin therapy within the last year. RESULTS: Interviews were conducted with 49 patients. Seventy percent were between 36 and 64 years old and reported taking between 1 and 18 different medications daily. Many (76%) received information about warfarin when first prescribed to them, 65% written and 60% verbal (answers reflect more than one response). Patients found content in the medication guide difficult to understand; 18% were unable to identify information about diet and 21% were unable to locate information about when to call their provider. Analysis showed that 19% had trouble with numeracy issues related to warfarin. Patients' suggestions of ways to convey warfarin information included more graphics, in-person counseling, and multilingual translations. CONCLUSION: This study demonstrates gaps in patients' understanding of warfarin therapy. Relying solely on the information in the FDA medication guide is insufficient to guarantee adequate understanding. Utilizing the suggestions from patients' feedback on other ways to deliver information should help future patients with different learning abilities and styles.
PMID: 25147159
ISSN: 0897-1900
CID: 1142602
Comments on "medical outcomes associated with nonmedical use of methadone and buprenorphine" [Letter]
Connors, Nicholas J; Hoffman, Robert S
PMID: 24998500
ISSN: 0736-4679
CID: 2912802
Falsely elevated salicylate level in a patient with hypertriglyceridemia [Meeting Abstract]
Biary, R; Kremer, A; Sauthoff, H; Nelson, LS; Goldfarb, D; Hoffman, RS; Howland, MA
ISI:000340298700244
ISSN: 1556-9519
CID: 2786332
Topical capsaicin cream used as a therapy for cannabinoid hyperemesis syndrome [Meeting Abstract]
Biary, R; Oh, A; Lapoint, J; Nelson, LS; Hoffman, RS; Howland, MA
ISI:000340298700238
ISSN: 1556-9519
CID: 2786342
Pediatric exposures to methadone and buprenorphine: Developing prevention strategies [Meeting Abstract]
Schwartz, L; Mercurio-Zappala, M; Howland, MA; Hoffman, RS; Su, M
ISI:000340298700097
ISSN: 1556-9519
CID: 2786382
Ingestion of compounded ointment leading to significant toxicity in a child [Meeting Abstract]
Lucyk, SN; Nelson, LS; Hoffman, RS; Howland, MA; Su, M
ISI:000340298700269
ISSN: 1556-9519
CID: 2786362
In response to "plasma exchange in patients with intermediate syndrome due to organophosphates" [Letter]
Kessler, Benjamin D; Sabharwal, Maneesha; Pak-Teng, Carol; Hoffman, Robert S
PMID: 24475491
ISSN: 1532-8171
CID: 1612102
Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013
Ridpath, Alison; Driver, Cynthia R; Nolan, Michelle L; Karpati, Adam; Kass, Daniel; Paone, Denise; Jakubowski, Andrea; Hoffman, Robert S; Nelson, Lewis S; Kunins, Hillary V
Outdoor electronic dance-music festivals (EDMFs) are typically summer events where attendees can dance for hours in hot temperatures. EDMFs have received increased media attention because of their growing popularity and reports of illness among attendees associated with recreational drug use. MDMA (3,4-methylenedioxymethamphetamine) is one of the drugs often used at EDMFs. MDMA causes euphoria and mental stimulation but also can cause serious adverse effects, including hyperthermia, seizures, hyponatremia, rhabdomyolysis, and multiorgan failure. In this report, MDMA and other synthetic drugs commonly used at dance festivals are referred to as "synthetic club drugs." On September 1, 2013, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) received reports of two deaths of attendees at an EDMF (festival A) held August 31-September 1 in NYC. DOHMH conducted an investigation to identify and characterize adverse events resulting in emergency department (ED) visits among festival A attendees and to determine what drugs were associated with these adverse events. The investigation identified 22 cases of adverse events; nine cases were severe, including two deaths. Twenty-one (95%) of the 22 patients had used drugs or alcohol. Of 17 patients with toxicology testing, MDMA and other compounds were identified, most frequently methylone, in 11 patients. Public health messages and strategies regarding adverse health events might reduce illnesses and deaths at EDMFs.
PMCID:5779530
PMID: 25522087
ISSN: 1545-861x
CID: 1606102
Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
Connors, Nicholas J; Sise, Meghan E; Nelson, Lewis S; Hoffman, Robert S; Smith, Silas W
High-dose methotrexate (MTX) can produce acute kidney injury, impairing MTX elimination. Continuous venovenous hemofiltration (CVVH) may enhance elimination in this setting, although its use is largely unstudied. A 79-year-old man received IV MTX for central nervous system lymphoma, and over a 34-h period his serum creatinine increased from 1.09 to 2.24 mg/dL. His serum MTX concentration (sMTX) at the end of this time period was 59.05 micromol/L. After urinary alkalinization and leucovorin and glucarpidase (CPDG2) treatment, sMTX decreased. Fluid overload ensued and CVVH was initiated. The initial MTX extraction ratio and clearance were 0.22 and 47.0 mL/min, respectively. No MTX extraction occurred at an sMTX of 0.15 micromol/L. Continuous venovenous hemodialysis was initiated, and sMTX further declined. CVVH may help eliminate MTX and provide renal replacement at moderate sMTX.
PMCID:4389132
PMID: 25859377
ISSN: 2048-8505
CID: 1532042